Treatment of Systemic Lupus Erythematosus with Severe Autoimmune Thrombocytopenia

Some patients with systemic lupus erythematosus develop severe autoimmune thrombocytopenia — a significant drop in platelet count that requires prompt intervention. This clinical scenario represents a distinct and serious complication of SLE that warrants a specific treatment approach.

Clinical Scenario

This protocol applies to patients with systemic lupus erythematosus presenting with severe autoimmune thrombocytopenia, defined by a platelet count below 20,000–30,000/mm³. At this threshold, the risk of bleeding and clinical consequences is such that active treatment is indicated.

Treatment goal: Platelet count above 30,000/mm³

Treatment Approach (Overview)

Acute management centres on high-dose glucocorticoids, including pulses of intravenous methylprednisolone, as the foundational intervention. Depending on the clinical response, additional immunotherapy agents may be combined in the acute phase.

Full sequencing, combination criteria, alternative agents, and the complete management algorithm are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2023-224762

For acute treatment of severe autoimmune thrombocytopenia, high-dose glucocorticoids (including pulses of intravenous methylprednisolone) (4/C), with or without intravenous immunoglobulin G (4/C), and/or rituximab (2b/B), and/or high-dose intravenous cyclophosphamide (4/C), followed by maintenance therapy with rituximab (2b/B), azathioprine (2b/C), mycophenolate (2b/C), or cyclosporine (4/C) should be considered.

A platelet number of 20–30 000/mm³ is typically used as the cut-off, below which therapy is indicated.

View source ↗